Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Immunomedics Q&A: using ADCs to tackle unmet needs in breast cancer

Immunomedics has developed an ADC called sacituzumab govitecan, which directly delivers chemotherapy SN-38 to TNBC tumours, which highly express Trop-2 and represents an unmet need within a highly treated cancer type. The company’s chief commercial officer Brendan Delaney explains the drug’s efficacious mechanism of action in this tumour type, as well as noting its success to date, particularly in tolerability and how Immunomedics is advancing the ADC in other Trop-2-expressing tumours.

Close
Close
Close

Go Top